Format

Send to

Choose Destination
J Subst Abuse Treat. 2014 Feb;46(2):128-33. doi: 10.1016/j.jsat.2013.08.006. Epub 2013 Oct 2.

The cost-effectiveness of depression treatment for co-occurring disorders: a clinical trial.

Author information

1
RAND Corporation, Santa Monica, CA 90401, USA. Electronic address: kwatkins@rand.org.

Abstract

The authors aimed to determine the economic value of providing on-site group cognitive behavioral therapy (CBT) for depression to clients receiving residential substance use disorder (SUD) treatment. Using a quasi-experimental design and an intention-to-treat analysis, the incremental cost-effectiveness and cost-utility ratio of the intervention were estimated relative to usual care residential treatment. The average cost of a treatment episode was $908, compared to $180 for usual care. The incremental cost effectiveness ratio was $131 for each point improvement of the BDI-II and $49 for each additional depression-free day. The incremental cost-utility ratio ranged from $9,249 to $17,834 for each additional quality adjusted life year. Although the intervention costs substantially more than usual care, the cost effectiveness and cost-utility ratios compare favorably to other depression interventions. Health care reform should promote dissemination of group CBT to individuals with depression in residential SUD treatment.

KEYWORDS:

Cognitive–Behavioral therapy; Cost-effectiveness; Depression

PMID:
24094613
PMCID:
PMC3840153
DOI:
10.1016/j.jsat.2013.08.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center